Mark Erlander

Mark Erlander is a declared insider of Cardiff Oncology, Inc., with filings sourced from SEC (Form 4). Between 14 December 2016 and 25 November 2022, the trades on record add up to 32 filings.

No open-market sale appears; the market trades are 4 purchases worth €41k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 14 share grants and 14 option exercises. 2022 to date brings 1 purchase and no sales.

A typical purchase (the median) is worth €9,519. Of 4 purchases, 2 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 50% of cases; the median change was -7.8%. Past outcomes like these are no guarantee of what comes next.

The record was last updated on 29 November 2022 with an open-market purchase (€14k) in Cardiff Oncology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.